The cost-effectiveness of treating chronic hepatitis B patients in a median endemic and middle income country

European Journal of Health Economics

Volumn 13, Issue 5, 2012, Pages 663-676

  Toy, Mehlika ^a,b   Onder, Fatih Oguz ^c   Idilman, Ramazan ^d   Kabacam, Gokhan ^d   Richardus, Jan Hendrik ^a   Bozdayi, Mithat ^e   Akdogan, Meral ^c   Kuloglu, Zarife ^e   Kansu, Aydan ^e   Schalm, Solko ^a,b   Yurdaydin, Cihan ^d  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b LiverDoc   (Netherlands)

^c TURKIYE YUKSEK IHTISAS HOSPITAL   (Turkey)

^d ANKARA UNIVERSITY   (Turkey)

^e Gaza University School of Medicine   (Turkey)

Author keywords

Antiviral therapy; Chronic hepatitis B; Cost effectiveness analysis; Middle income; Turkey

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON; TENOFOVIR; VIRUS DNA;

ADD ON THERAPY; AGE DISTRIBUTION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; CALIBRATION; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DATA BASE; DECOMPENSATED LIVER CIRRHOSIS; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; ENDEMIC DISEASE; HEPATITIS B; HIDDEN MARKOV MODEL; HUMAN; INCOME; LIVER CANCER; LIVER CIRRHOSIS; MIDDLE INCOME GROUP; MONOTHERAPY; MORBIDITY; MORTALITY; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SALVAGE THERAPY; TREATMENT RESPONSE; TURKEY (REPUBLIC); VIRUS CARRIER;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; FEMALE; HEPATITIS B, CHRONIC; HUMANS; INCOME; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; PREVALENCE; QUALITY-ADJUSTED LIFE YEARS; SENSITIVITY AND SPECIFICITY; TURKEY; YOUNG ADULT;

EID: 84865622856     PISSN: 16187598     EISSN: 16187601     Source Type: Journal    
DOI: 10.1007/s10198-012-0413-8     Document Type: Article

References (58)

1. D Lavanchy 2004 Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures J. Viral Hepat. 11 2 97 107 14996343 10.1046/j.1365-2893.2003.00487.x 1:STN:280:DC%2BD2c7gs1Whug%3D%3D
2. European Association For The Study of The Liver 2009 EASL clinical practice guidelines: management of chronic hepatitis B J. Hepatol. 50 2 227 242 10.1016/j.jhep.2008.10.001
3. AS Lok BJ McMahon 2009 Chronic hepatitis B: update 2009 Hepatology 50 661 662 19714720 10.1002/hep.23190
4. P Ferenci M Fried D Labrecque J Bruix M Sherman M Omata J Heathcote T Piratsivuth M Kew JA Otegbayo SS Zheng S Sarin SS Hamid SB Modawi W Fleig S Fedail A Thomson A Khan P Malfertheiner G Lau FJ Carillo J Krabshuis A Le Mair 2010 World Gastroenterology O: Hepatocellular carcinoma (HCC): a global perspective J. Clin. Gastroenterol. 44 4 239 245 10.1097/MCG.0b013e3181d46ef2 20216082 10.1097/MCG.0b013e3181d46ef2
5. Yurdaydin, C.; Akarca, U.: Treatment of chronic hepatitis B with telbuvidine: wise hepatologists needed in hepatitis B endemic countries where treatment options are limited. Liver Int. 31(5), 589-591 (2011)
6. Toy, M.; Onder, F.O.; Wormann, T.; Bozdayi, M.; Schalm, S.W.; Borsboom, G.J.; Idilman, R.; Richardus, J.H.; Yurdaydin, C.: Age- and region-specific hepatitis B prevalence in Turkey estimated using generalized linear mixed models: a systematic review. BioMed Central Infect. Dis. 11, 337 (2011)
7. Turkish Statistics Institute: In.; p. http://www.tuik.gov.tr/Start.do. (2010)
8. SJ Hadziyannis NC Tassopoulos EJ Heathcote TT Chang G Kitis M Rizzetto P Marcellin SG Lim Z Goodman MS Wulfsohn S Xiong J Fry CL Brosgart 2003 Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B N. Engl. J. Med. 348 9 800 807 12606734 10.1056/NEJMoa021812 1:CAS:528:DC%2BD3sXhsFKju7w%3D
9. HL Janssen M van Zonneveld H Senturk S Zeuzem US Akarca Y Cakaloglu C Simon TM So G Gerken RA de Man HG Niesters P Zondervan B Hansen SW Schalm 2005 Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial Lancet 365 9454 123 129 15639293 10.1016/S0140-6736(05)17701-0 1:CAS:528:DC%2BD2MXhvF2gsQ%3D%3D
10. F Kanwal IM Gralnek P Martin GS Dulai M Farid BM Spiegel 2005 Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis Ann. Intern. Med. 142 10 821 831 15897532 1:CAS:528: DC%2BD2MXltFCnu7o%3D
11. G Fattovich F Bortolotti F Donato 2008 Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors J. Hepatol. 48 335 352 18096267 10.1016/j.jhep.2007.11.011
12. G Fattovich M Pantalena I Zagni G Realdi SW Schalm E Christensen 2002 Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients Am. J. Gastroenterol. 97 11 2886 2895 12425564 10.1111/j.1572-0241.2002.07057.x
13. G Fattovich G Giustina SW Schalm S Hadziyannis J Sanchez-Tapias P Almasio E Christensen K Krogsgaard F Degos M Carneiro de Moura, et al. 1995 Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis Hepatology 21 1 77 82 7806171 1:STN:280:DyaK2M7gsVOrsw%3D%3D
14. G Realdi G Fattovich S Hadziyannis SW Schalm P Almasio J Sanchez-Tapias E Christensen G Giustina F Noventa 1994 Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. The Investigators of the European Concerted Action on Viral Hepatitis (EUROHEP) J. Hepatol. 21 4 656 666 7814813 10.1016/S0168-8278(94)80115-0 1:STN:280: DyaK2M7hsVehsA%3D%3D
15. F Kanwal M Farid P Martin G Chen IM Gralnek GS Dulai BM Spiegel 2006 Treatment alternatives for hepatitis B cirrhosis: a cost-effectiveness analysis Am. J. Gastroenterol. 101 9 2076 2089 16968510 10.1111/j.1572-0241.2006.00769.x
16. TT Chang RG Gish R de Man A Gadano J Sollano YC Chao AS Lok KH Han Z Goodman J Zhu A Cross D DeHertogh R Wilber R Colonno D Apelian 2006 A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B N. Engl. J. Med. 354 10 1001 1010 16525137 10.1056/NEJMoa051285 1:CAS:528: DC%2BD28XitFWms7Y%3D
17. CL Lai D Shouval AS Lok TT Chang H Cheinquer Z Goodman D DeHertogh R Wilber RC Zink A Cross R Colonno L Fernandes 2006 Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B N. Engl. J. Med. 354 10 1011 1020 16525138 10.1056/NEJMoa051287 1:CAS:528:DC%2BD28XitFWlsrY%3D
18. RJ Colonno RE Rose K Pokornowski CJ Baldick B Eggers D Xu A Cross DJ Tenney 2007 Four year assessment of entecavir resistance in nucleoside naïve and lamivudine refractory patients J. Hepatol. 46 Suppl. 1 S294 10.1016/S0168-8278(07)62379-4
19. CL Lai J Dienstag E Schiff NW Leung M Atkins C Hunt N Brown M Woessner R Boehme L Condreay 2003 Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B Clin. Infect. Dis. 36 6 687 696 12627352 10.1086/368083 1:CAS:528:DC%2BD3sXjtVKqtbk%3D
20. DN Moskovitz C Osiowy E Giles G Tomlinson EJ Heathcote 2005 Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance J. Viral Hepat. 12 4 398 404 15985011 10.1111/j.1365-2893.2005.00613.x 1:STN:280:DC%2BD2MzjsV2itA%3D%3D
21. YS Lee DJ Suh YS Lim SW Jung KM Kim HC Lee YH Chung YS Lee W Yoo SO Kim 2006 Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy Hepatology 43 6 1385 1391 16729316 10.1002/hep.21189 1:CAS:528:DC%2BD28XmsF2msr8%3D
22. CH Chen JH Wang CM Lee CH Hung TH Hu JC Wang SN Lu CS Changchien 2006 Virological response and incidence of adefovir resistance in lamivudine-resistant patients treated with adefovir dipivoxil Antivir. Ther. 11 6 771 778 17310821 1:CAS:528:DC%2BD28XhtFKgsLjJ
23. JE Yeon W Yoo SP Hong YJ Chang SK Yu JH Kim YS Seo HJ Chung MS Moon SO Kim KS Byun CH Lee 2006 Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil Gut 55 10 1488 1495 16461777 10.1136/gut.2005.077099 1:CAS:528:DC%2BD28XhtFeht7rJ
24. YF Liaw JJ Sung WC Chow G Farrell CZ Lee H Yuen T Tanwandee QM Tao K Shue ON Keene JS Dixon DF Gray J Sabbat 2004 Lamivudine for patients with chronic hepatitis B and advanced liver disease N. Engl. J. Med. 351 15 1521 1531 15470215 10.1056/NEJMoa033364 1:CAS:528:DC%2BD2cXot1Kls7w%3D
25. RJ Colonno R Rose CJ Baldick S Levine K Pokornowski CF Yu A Walsh J Fang M Hsu C Mazzucco B Eggers S Zhang M Plym K Klesczewski DJ Tenney 2006 Entecavir resistance is rare in nucleoside naive patients with hepatitis B Hepatology 44 6 1656 1665 17133475 10.1002/hep.21422 1:CAS:528:DC%2BD2sXislOjtg%3D%3D
26. DJ Tenney RE Rose CJ Baldick KA Pokornowski BJ Eggers J Fang MJ Wichroski D Xu J Yang RB Wilber RJ Colonno 2009 Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy Hepatology 49 5 1503 1514 19280622 10.1002/hep.22841 1:CAS:528:DC%2BD1MXlslKmurw%3D
27. EJ Heathcote P Marcellin M Buti E Gane RA De Man Z Krastev G Germanidis SS Lee R Flisiak K Kaita M Manns I Kotzev K Tchernev P Buggisch F Weilert OO Kurdas ML Shiffman H Trinh S Gurel A Snow-Lampart K Borroto-Esoda E Mondou J Anderson J Sorbel F Rousseau 2011 Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B Gastroenterology 140 1 132 143 10.1053/j.gastro.2010.10.011 20955704 10.1053/j.gastro.2010.10.011 1:CAS:528:DC%2BC3cXhsFyltLvF
28. F van Bommel T Wunsche S Mauss P Reinke A Bergk D Schurmann B Wiedenmann T Berg 2004 Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection Hepatology 40 6 1421 1425 15565615 10.1002/hep.20464
29. Sarin, N.; Yim, C.; Feld, J.J.; Heathcote, E.J.; Wong, D.K.: Tenofovir is effective salvage therapy for nucleoside-resistant hepatitis B. abstract nr: 454, AASLD 2009 Boston (2009)
30. Van Bommel, F.; De Man, R.; Ferenci, P.; Reijnders, J.G.; Bronowicki, J.P.; Fulop, B.; Wedemeyer, H.; Erhardt, A.; Hueppe, D.; Bourliere, M.; Sarrazin, C.; Trojan, J.; Buggisch, P.; Petersen, J.; Spenger, U.; Brost, S.; Pariente, A.; Schuchmann, M.; Wasmuth, H.E.; Deterding, K.; Rutter, K.; Feucht, H.H.; Wiedenmann, B.; Berg, T.: Long-term follow-up evaluation of the efficacy and safety of tenofovir disoproxil fumarate (TDF) in a european multicenter (nucleos(t)ide experienced) hepatitis B virus HBV infected cohort. abstract nr: 221, AASLD 2009 Boston (2009)
31. JG Reijnders HL Janssen 2008 Potency of tenofovir in chronic hepatitis B: mono or combination therapy? J. Hepatol. 48 3 383 386 18191272 10.1016/j.jhep.2007.12.006 1:CAS:528:DC%2BD1cXhsl2msr0%3D
32. GK Lau T Piratvisuth KX Luo P Marcellin S Thongsawat G Cooksley E Gane MW Fried WC Chow SW Paik WY Chang T Berg R Flisiak P McCloud N Pluck 2005 Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B N. Engl. J. Med. 352 26 2682 2695 15987917 10.1056/NEJMoa043470 1:CAS:528:DC%2BD2MXls1SktL8%3D
33. Marcellin, P.; Bonino, F.; Lau, G.K.; Farci, P.; Yurdaydin, C.; Piratvisuth, T.; Jin, R.; Gurel, S.; Lu, Z.M.; Wu, J.; Popescu, M.; Hadziyannis, S.: Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology 136(7), 2169-2179 e2161-2164 (2009)
34. WG Cooksley T Piratvisuth SD Lee V Mahachai YC Chao T Tanwandee A Chutaputti WY Chang FE Zahm N Pluck 2003 Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B J. Viral Hepat. 10 4 298 305 12823597 10.1046/j.1365-2893.2003.00450.x 1:STN:280:DC%2BD3szksVOquw%3D%3D
35. T Piratvisuth G Lau YC Chao R Jin A Chutaputti QB Zhang T Tanwandee P Button M Popescu 2008 Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B Hepatol. Int. 2 1 102 110 19669285 10.1007/s12072-007-9022-5
36. RL Fleurence CS Hollenbeak 2007 Rates and probabilities in economic modelling: transformation, translation and appropriate application Pharmacoeconomics 25 1 3 6 17192114 10.2165/00019053-200725010-00002
37. PT Kennedy N Phillips J Chandrasekhar R Jacobs M Jacobs G Dusheiko 2008 Potential and limitations of lamivudine monotherapy in chronic hepatitis B: evidence from genotyping Liver Int. 28 5 699 704 18433396 10.1111/j.1478-3231. 2008.01717.x 1:CAS:528:DC%2BD1cXmsFKisbw%3D
38. D Shouval CL Lai TT Chang H Cheinquer P Martin G Carosi S Han S Kaymakoglu R Tamez J Yang D Tenney H Brett-Smith 2009 Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy J. Hepatol. 50 2 289 295 19070393 10.1016/j.jhep.2008.10.017 1:CAS:528:DC%2BD1MXntVGhtg%3D%3D
39. JG Reijnders MJ Perquin N Zhang BE Hansen HL Janssen 2010 Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B Gastroenterology 139 2 491 498 20381492 10.1053/j.gastro.2010.03.059 1:CAS:528:DC%2BC3cXpsVGnu7s%3D
40. P Marcellin GK Lau F Bonino P Farci S Hadziyannis R Jin ZM Lu T Piratvisuth G Germanidis C Yurdaydin M Diago S Gurel MY Lai P Button N Pluck 2004 Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B N. Engl. J. Med. 351 12 1206 1217 15371578 10.1056/NEJMoa040431 1:CAS:528:DC%2BD2cXns12rsr0%3D
41. EB Keeffe S Zeuzem RS Koff DT Dieterich R Esteban-Mur EJ Gane IM Jacobson SG Lim N Naoumov P Marcellin T Piratvisuth F Zoulim 2007 Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B Clin. Gastroenterol. Hepatol. 5 8 890 897 10.1016/j.cgh.2007.05.004 17632041 10.1016/j.cgh.2007.05.004
42. TT Chang 2009 On-treatment monitoring of HBV DNA levels: predicting response and resistance to oral antiviral therapy at week 24 versus week 48 Hepatol. Int. 3 Suppl 1 16 23 19669242 10.1007/s12072-009-9143-0
43. CL Lai E Gane YF Liaw CW Hsu S Thongsawat Y Wang Y Chen EJ Heathcote J Rasenack N Bzowej NV Naoumov AM Di Bisceglie S Zeuzem YM Moon Z Goodman G Chao BF Constance NA Brown 2007 Telbivudine versus lamivudine in patients with chronic hepatitis B N. Engl. J. Med. 357 25 2576 2588 18094378 10.1056/NEJMoa066422 1:CAS:528:DC%2BD2sXhsVKht7nF
44. AS Hadziyannis PV Mitsoula SJ Hadziyannis 2007 Prediction of long-term maintenance of virologic response during lamivudine treatment in HBeAg-negative chronic hepatitis B Hepatology 46 Suppl. 1 667A
45. Turkish Health Ministry: Turkish Health Ministry Drugs and pharmaceutical head quarters. vol. 2009, December http://www.iegm.gov.tr/Default.aspx?sayfa= fiyat-listesi (2010)
46. AR Levy KV Kowdley U Iloeje E Tafesse J Mukherjee R Gish N Bzowej AH Briggs 2008 The impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected persons Value Health 11 3 527 538 18179664 10.1111/j.1524-4733.2007.00297.x
47. Gold, M.R.; Siegel, J.E.; Russel, L.B.; Weinstein, M.G.: Cost-Effectiveness in Health and Medicine. Oxford University Press, New York (1996)
48. MF Drummond TO Jefferson 1996 Guidelines for authors and peer reviewers of economic submissions to the BMJ the BMJ economic evaluation working party BMJ 313 7052 275 283 8704542 10.1136/bmj.313.7052.275 1:STN:280: DyaK28zit1Kkug%3D%3D
49. World Health Organization: WHO guide to cost-effectiveness. In.; p. http://www.who.int/choice/publications/p-2003-generalised-cea.pdf (2003)
50. Z Karasu M Akyildiz M Kilic M Zeytunlu U Aydin F Tekin F Yilmaz T Ozacar U Akarca G Ersoz F Gunsar T Ilter MR Lucey 2007 Living donor liver transplantation for hepatitis B cirrhosis J. Gastroenterol. Hepatol. 22 12 2124 2129 10.1111/j.1440-1746.2006.04782.x 18031369 10.1111/j.1440-1746.2006.04782.x
51. Woo, G.; Tomlinson, G.; Nishikawa, Y.; Kowgier, M.; Sherman, M.; Wong, D.K.; Pham, B.; Ungar, W.J.; Einarson, T.R.; Heathcote, E.J.; Krahn, M.: Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and bayesian meta-analyses. Gastroenterology 139(4), 1218-1229 e1215 (2010). doi: 10.1053/j.gastro.2010.06.042
52. US Akarca 2008 Chronic hepatitis B. A guideline to diagnosis, approach, management, and follow-up 2007. Turkish Association for the Study of Liver Turk. J. Gastroenterol. 19 4 207 230 19119479
53. M Toy IK Veldhuijzen RA de Man JH Richardus SW Schalm 2009 Potential impact of long-term nucleoside therapy on the mortality and morbidity of active chronic hepatitis B Hepatology 50 3 743 751 19585616 10.1002/hep.23061 1:CAS:528:DC%2BD1MXhtFKntL7F
54. JB Wong RS Koff F Tine SG Pauker 1995 Cost-effectiveness of interferon-alpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B Ann. Intern. Med. 122 9 664 675 7702228 1:STN:280: DyaK2M3hs1Oqtw%3D%3D
55. DE Spackman DL Veenstra 2008 A cost-effectiveness analysis of currently approved treatments for HBeAg-positive chronic hepatitis B Pharmacoeconomics 26 11 937 949 18850763 10.2165/00019053-200826110-00006
56. Shepherd, J.; Jones, J.; Takeda, A.; Davidson, P.; Price, A.: Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation. Health Technol. Assess. 10(28), iii-iv, xi-xiv, 1-183 (2006)
57. M Buti M Brosa MA Casado M Rueda R Esteban 2009 Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B J. Hepatol. 51 4 640 646 10.1016/j.jhep.2009.04.013 19576651 10.1016/j.jhep.2009.04.013 1:CAS:528:DC%2BD1MXhtFagtrbF
58. M Barbieri M Drummond R Willke J Chancellor B Jolain A Towse 2005 Variability of cost-effectiveness estimates for pharmaceuticals in Western Europe: lessons for inferring generalizability Value Health 8 1 10 23 15841890 10.1111/j.1524-4733.2005.03070.x